AGArtyom V. Gorbatykh

Artyom V. Gorbatykh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Artyom V. Gorbatykh has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Surgical Management of Congenital Heart Disease in the Russian Federation for 2025.

    by Ilya A. Soynov, Alexey I. Kim, Ruben Rudolfovich Movsesyan, Pavel Viktorovich Teplov, Aleksandr Yu. Miller, Yuriy Yu. Kulyabin, Aleksey N. Arkhipov, Anton A. Avramenko, Kirill V. Gorbatikov, Artem V. Gorbatykh, et al.

    Introduction: Systematic monitoring of outcomes in patients with congenital heart disease (CHD) is essential for improving the quality of care. Since 2024, a national multicenter digital registry designed to consolidate data from the country’s leading expert centers has been undergoing pilot implementation in the Russian Federation. Objective: To assess surgical volumes, the distribution of diagnoses, and in-hospital mortality associated with treatment for CHD and cardiac arrhythmias in the Russian Federation using 2025 registry data. Methods: We retrospectively analyzed de-identified data from 15,634 patients treated at 32 cardiac surgery centers in the Russian Federation that provide care to patients younger than 18 years with CHD. Procedural complexity was assessed using the RACHS II risk-stratification system. Outcomes were analyzed by age group, including neonates with low birth weight. Results: Overall in-hospital mortality was 1.30% (vs. 1.42% in 2024). Open surgical procedures accounted for 48.3% of interventions, transcatheter procedures for 37.6%, and procedures for cardiac arrhythmias for 12.8%. The most common CHD diagnoses were atrial septal defect (23.96%), patent ductus arteriosus (22.42%), and ventricular septal defect (15.47%).The highest mortality was observed among neonates undergoing surgerywith cardiopulmonary bypass (9.5%). Conclusion: The 2025 data confirm a sustained decline in overall mortalityand support the effectiveness of implementing national standards. Further improvement in neonatal surgery for complex defects remains a priority. Implementation of a unified system enabling patient-level identification and personalized assessment of treatment effectiveness is also essential. Received 8 July 2026. Revised 12 July 2026. Accepted 20 August 2026. Funding The study did not have sponsorship. Conflict of InterestThe authors declare no conflict of interest. Contribution of the authorsConception and study design: I.A. Soynov, R.R. Movsesyan, P.V. Teplov, A.A. Svobodov, E.V. Krivoshchekov, E.S. Tarasyuk Data collection and analysis: I.A. Soynov, A.Yu. Miller, Yu.Yu. Kulyabin, A.N. Arkhipov, A.A. Avramenko, K.V. Gorbatikov, A.V. Gorbatykh, K.A. Nalimov, S.A. Kovalev, A.A. Svobodov, A.A. Shikhranov, M.V. Plotnikov, O.A. Egunov, V.A. Belov, I.V. Gladyshev, K.B. Kazantsev, O.Yu. Kornoukhov, A.V. Nokhrin, D.Yu. Petrushenko, E.S. Efanov, I.K. Khalivopulo, D.V. Ryabtsev, Yu.A. Sobolev, V.N. Medvedev, R.Yu. Gavrilov, N.I. Pavlov Statistical analysis: I.A. Soynov, P.V. Teplov, K.A. Nalimov, M.A. Abramyan, S.A. Kovalev Drafting the article: I.A. Soynov, A.Yu. Miller, Yu.Yu. Kulyabin, A.A. Avramenko, K.V. Gorbatikov, A.V. Gorbatykh, K.A. Nalimov, A.V. Kauk, E.V. Krivoshchekov, E.N. Amansakhatova Critical revision of the article: A.I. Kim, R.R. Movsesyan, M.A. Abramyan, E.V. Krivoshchekov, E.S. Tarasyuk Final approval of the version to be published: all authors

  • Open Access

    Early discontinuation of dual antiplatelet therapy after PCI in patients at high bleeding risk: an OCT-guided clinical case

    by A. A. Prokhorikhin, Yu. V. Kukushkina, D. D. Zubarev, A. V. Gorbatykh, K. A. Rzaeva, А. А. Прохорихин, Ю. В. Кукушкина, Д. Д. Зубарев, А. В. Горбатых, К. А. Рзаева

    Background. Optimizing the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains challenging, especially in patients with high bleeding risk and diabetes mellitus, where stent thrombosis risk is significantly increased due to delayed endothelialization. Objective. To demonstrate the safety of early DAPT discontinuation based on individual assessment of stent endothelialization using optical coherence tomography (OCT). Materials and Methods. We present a clinical case of a 71-year-old female with type II diabetes, atrial fibrillation (CHA2DS2-VASc score of 6), functional class II exertional angina, and a history of left anterior descending (LAD) artery stenting. Risk stratification indicated a high hemorrhagic status: HAS-BLED score of 3, PRECISE-DAPT score of 17, ARC-HBR score of 2, and a CRUSADE score of 49 (corresponding to an 11.9 % risk of major bleeding). Baseline OCT revealed significant narrowing: the minimal lumen area in the LAD was 3.51 mm² (56 % area stenosis), and 2.08 mm² in the right coronary artery (RCA) (72 % area stenosis). Stenting of LAD and right coronary artery was performed using amphilimus-eluting polymer-free stents. DAPT discontinuation was planned at 1 month contingent on sufficient endothelialization per control OCT. Results. Follow-up OCT at one month demonstrated neointimal coverage of 81.18 % of the struts in the LAD and 95.9 % in the RCA. No evidence of stent thrombosis or restenosis was observed. The patient was transitioned to clopidogrel monotherapy, alongside ongoing anticoagulant therapy for the prevention of thrombotic complications associated with atrial fibrillation. During the one-year follow-up period, no ischemic or hemorrhagic adverse events were registered, and there was no recurrence of angina symptoms. Conclusion. The application of OCT for the evaluation of stent strut endothelialization provides a robust rationale for shortening DAPT duration to 1 month in patients with high hemorrhagic risk. This strategy minimizes bleeding threats without escalating the incidence of ischemic events, even in the presence of concomitant diabetes mellitus and multiple comorbidities.

  • Open Access

    Transcatheter atrioventricular valve-in-valve re-replacement with balloon-expandable prostheses: contemporary clinical relevance and place among redo valve interventions

    by Artem V. Gorbatykh

    Introduction: The steadily increasing number of patients with structural degeneration of bioprosthetic heart valves necessitates the search for alternatives to redo open surgery, which is associated with high operative risk due to resternotomy, adhesions, repeat cardiopulmonary bypass, and an unfavorable comorbidity profile. In this context, transcatheter valve-in-valve re-replacement has emerged as one of the key management strategies for this patient population, especially in the technically most challenging atrioventricular positions. Objective: To assess the contemporary clinical relevance of transcatheter atrioventricular re-replacement and define its place in the structure of redo interventions based on the clinical case series reported by R.S. Tarasov et al. and current international literature. Results: This article reviews the technical and clinical aspects of mitral and tricuspid re-replacement using balloon-expandable prostheses. Recent meta-analyses have shown that the valve-in-valve technique is non-inferior to surgical re-replacement in terms of survival, while being associated with significantly lower rates of stroke, bleeding, and acute kidney injury. Particular attention is paid to the role of multislice computed tomography in preventing left ventricular outflow tract obstruction during mitral interventions, to the principles of balloon-expandable prosthesis positioning in the atrioventricular position, and to the possibility of minimizing anesthetic support during tricuspid re-replacement. At the same time, the limitations of the current evidence base and several unresolved issues are emphasized, including implanted device durability, the risk of residual gradients, and paravalvular regurgitation. Conclusion: At present, transcatheter valve-in-valve re-replacement in atrioventricular positions should be regarded not merely as an alternative for patients at prohibitive risk, but as a clinically justified component of the contemporary treatment strategy capable of substantially reducing procedural burden and accelerating rehabilitation. Nevertheless, the definitive determination of its role requires prospective studies with long-term outcome assessment. Received 23 June 2026. Revised 24 June 2026. Accepted 24 June 2026. Funding The study did not have sponsorship.

  • Open Access

    EVOLUTION OF CORONARY STENTS: FROM EARLY EXPERIMENTS TO MODERN TECHNOLOGIES

    by Polina A. Kuznetsova, Artem V. Gorbatykh, Ksenia A. Rzaeva, Alexey A. Prokhorikhin, Ekaterina P. Kolesova, Alexey L. Maslyansky, Yana G. Toropova, Yuriy A. Skorik, Mikhail M. Galagudza, Alexandra O. Konradi, et al.

    Highlights This review presents a systematic overview of scientific achievements in the development and use of coronary stents. It includes an analysis of key studies addressing various aspects of their performance. The article examines existing generations of coronary stents, materials used in their manufacture, design features, and also describes the latest advancements in this field.   Abstract To trace the evolution of coronary stents and identify promising directions in the development of endovascular surgery.An analytical literature review was conducted, including results from major randomized clinical trials and meta-analyses published in leading cardiology journals between 1994 and 2025.The introduction of coronary stent implantation technology reduced the incidence of thrombosis and the need for repeat revascularization compared to balloon angioplasty. However, a high risk of restenosis limited their use. The emergence of drug-eluting stents in the 2000s led to a sharp decrease in neointimal hyperplasia and repeat interventions but was associated with a risk of late thrombosis. Modern generations of stents demonstrate improved efficacy and safety. Bioresorbable stents were an innovative development but failed to show superiority in large randomized trials. Currently, stents incorporating novel anti-inflammatory agents (such as colchicine) are under development. The evolution of coronary stents reflects the pursuit of an optimal biocompatible device that induces minimal inflammatory response, promotes rapid vascular wall healing, and eliminates the need for prolonged dual antiplatelet therapy. A literature search was conducted in the PubMed electronic database for publications from 1994 to 2025. The following keywords were used: «coronary stent», «bare metal stent», «drug-eluting stent», «polymer-free», and «bioresorbable scaffold». The review included clinical studies, systematic reviews, meta-analyses, randomized controlled trials, and comparative studies relevant to the topic of analysis.


  • Open Access

    A RARE CLINICAL CASE OF BILATERAL PULMONARY VEIN ATRESIA IN NEWBORN

    by Ksenia A. Rzaeva, Ilya A. Soynov, Polina A. Kuznetsova, Elena P. Matveeva, Anna A. Lyapunova, Artem V. Gorbatykh, Ксения Асифовна Рзаева, Илья Александрович Сойнов, Полина Анатольевна Кузнецова, Елена Павловна Матвеева, et al.

    Highlights Bilateral pulmonary vein atresia is an extremely rare congenital heart disease.   Abstract Pulmonary vein atresia is a rare congenital heart defect with a high morbidity and mortality rate. This condition develops due to abnormal connections between the pulmonary veins and the left atrium. Congenital heart defect has a poor prognosis and patients die due to secondary pulmonary hypertension, hemoptysis, pulmonary edema or congestive heart failure. We report a rare case of a newborn with anomaly of pulmonary venous return: bilateral pulmonary vein aplasia.

  • Open Access

    MORPHOFUNCTIONAL FEATURES OF PULMONARY ARTERY ATRESIA WITH INTACT INTERVENTRICULAR SEPTUM AND METHODS FOR VISUALIZING DEFECTS. REVIEW ARTICLE

    by Ксения Асифовна Рзаева, Polina A. Kuznetsova, Anna A. Lyapunova, Елена Павловна Матвеева, Ilya A. Soynov, Artem V. Gorbatykh, Илья Александрович Сойнов

    Highlights Pulmonary artery atresia with intact interventricular septum is a rare congenital heart defect that depends on the ductus.   Resume Pulmonary artery atresia with intact interventricular septum is a rare and heterogeneous congenital heart disease, belonging to the group of so-called “blue” defects. The anatomical and physiological spectrum of the defect is variable with varying degrees of tricuspid valve and right ventricular hypoplasia, from a simple membranous form with a well-developed RV to severe pancreatic hypoplasia with myocardial sinusoids and right ventricular-coronary dependent blood flow. Transthoracic echocardiography is considered the “gold standard” for diagnosis, while additional imaging techniques like computed tomography and cardiac catheterization can be used to further characterize the structural features of this anomaly. In this review, we present an overview of the morphology and physiology of right-sided heart chambers in patients with pulmonary artery atresia with an intact interventricle septum.

  • Open Access

    Surgical management of congenital heart diseases in the Russian Federation: national registry data for 2024

    by Ilya A. Soynov, Алексей Иванович Ким, Ruben R. Movsesyan Movsesyan, Павел Викторович Теплов, Александр Юрьевич Миллер, Yuriy Yu. Kulyabin, Анон Алексеевич Авраменко, Кирилл Виктрович Горбатиков, Artem V. Gorbatykh, Константин Александрович Налимов, et al.

    Introduction. Congenital heart diseases (CHDs) remain a leading cause ofinfant mortality and disability, underlining their high medico-social significance.In the context of rapid technological advancements, evolving demographicindicators, and improvements in prenatal diagnostics, systemic monitoring of treatment outcomes at the national level has become critically important. The national registry facilitates an objective assessment of current cardiac surgical care effectiveness nationwide, helps identify regional trends, and determines priority areas for the implementation of modern hybrid and endovascular protocols. Objective. To evaluate the current status and outcomes of surgical treatment for congenital heart diseases (CHD) in the Russian Federation based on the 2024 national multicenter registry data. Methods. A retrospective analysis of 14,640 surgical procedures performed across 31 cardiac surgery centers was conducted. The RACHS II scoring system was utilized for risk stratification. The study assessed hospital mortality rates, pathology distribution, and the efficacy of various surgical strategies. Results. The overall hospital mortality rate was 1.42 %. Endovascular procedures accounted for a significant proportion (38.4 %) of interventions. In the interventional arrhythmia segment (n = 1,342), zero mortality was achieved. The highest risk remains in the neonatal group (6.6 % mortality). Analysis of palliative care revealed the superiority of the hybrid approach: ductal stenting in duct-dependent patients showed half the mortality rate (4.95 %) compared to the surgical systemic-to-pulmonary artery shunt (9.74 %). Complex reconstructions (Norwood procedure) remain a high-risk area. Conclusion. The national pediatric cardiac surgery registry demonstrates high efficacy and safety for routine interventions. There is a distinct trend towards replacing open surgery with endovascular techniques. Centralization of care for critical CHDs in expert centers and the adoption of hybrid technologies are key factors for further improving outcomes.


  • Open Access

    Colchicine in modern cardiology: opportunities, limitations and promising results. An analytical review of the recent clinical trial outcomes

    by E. P. Kolesova, A. L. Maslyanskiy, Ya. G. Toropova, Yu. A. Skorik, K. A. Malyshkin, A. V. Gorbatykh, M. M. Galagudza, A. O. Konradi, E. V. Shlyakhto

    Background . Colchicine, traditionally used for gout treatment, has recently emerged as a promising therapeutic option for coronary artery disease (CAD) due to its anti-inflammatory properties. However, its use is accompanied by conflicting clinical data and potential risks. Objective . To systematize current evidence on the efficacy and safety of colchicine in cardiovascular diseases, identifying key areas of certainty and uncertainty. Design and methods . We analyzed 35 clinical studies (2021-2025), including randomized controlled trials (LoDoCo2, COLCOT, CLEAR), meta-analyses and cohort studies. The study was supported by the Russian Science Foundation (Agreement No. 25-15-20110). Results . Proven benefits: 28 % reduction in cardiovascular events in chronic CAD; atherosclerotic plaque stabilization (+ 34,2 μm fibrous cap thickness); 33 % reduction in postoperative atrial fibrillation. Controversial data: no benefit in acute coronary syndrome (odds ratio (OR) 0,99); increased dementia risk with long-term use (OR 1,45). Safety concerns: gastrointestinal complications (+ 3,6 %); trend toward increased non-cardiac mortality (+ 38 %); dose-dependent increase in dementia risk (+ 45 %). Conclusion . Colchicine represents a promising tool for secondary prevention of atherothrombosis, combining centuries of clinical experience with modern understanding of inflammatory mechanisms. Its niche included patients with chronic CAD and persistent inflammatory activity, where it complements standard therapy without increasing bleeding risk, unlike more aggressive antithrombotic strategies. Further research should clarify its role in acute settings and optimize dosing regimens considering individual safety profiles.

  • Open Access

    Characteristics of a self-expanding anatomically shaped valve for prosthetic replacement of the right ventricular outflow tract

    by S. N. Manukyan, I. A. Soynov, S. V. Vladimirov, D. A. Khelimsky, K. A. Rzaeva, A. V. Voytov, A. V. Gorbatykh, N. R. Nichay, Yu. Yu. Kulyabin, I. Yu. Zhuravleva, et al.

    Background . Patients following radical corrections of conotruncal congenital heart defects often develop right ventricular outflow tract dysfunctions as the child grows. It is well known that repeat surgical interventions, in addition to technical challenges, are associated with high risks and mortality. With advancements in endovascular surgery, transcatheter prosthetic right ventricular outflow tract (RVOT) replacement has become a viable alternative to thoracotomy surgery for a specific patient group. However, the choice of the "ideal" valve for transcatheter interventions remains a subject of debate. Objective . The aim of this study was to develop a valve for transcatheter implantation into the pulmonary artery position, considering anatomical variations of the RVOT, and to evaluate the hydrodynamic properties of the valve in vitro using bench testing. Material and methods . Based on the data obtained from a retrospective analysis of patients after radical correction of conotruncal congenital heart defects, a team of researchers from the Bioprosthetics Laboratory at the Center for New Surgical Technologies of National Medical Research Center n.a. Academician E.N. Meshalkin developed a prototype of a self-expanding nitinol frame for transcatheter pulmonary artery replacement. Conclusions . The prototype of the first domestically produced self-expanding pulmonary bioprosthesis for transcatheter implantation with an anatomically shaped nitinol frame demonstrated optimal hydrodynamic properties during the initial stages of preclinical testing. The anatomical design of the frame allows for valve implantation into the native right ventricular outflow tract without prior stenting.

  • Implantation of transcatheter self-expanding valve through hybrid approach: acute experiment on a large animal model

    by K.A. Rzaeva, S.N. Manukyan, A.V. Gorbatykh, I.YU. Zhuravleva, S.V. Vladimirov, I.A. Soynov

    Objective. To evaluate the properties of original transcatheter self-expanding pulmonary artery valve and to perform implantation in vivo on a large laboratory animal. Material and methods. A healthy 8-month-old female white pig weighing 66 kg underwent acute experimental procedure. Original transcatheter valve was implanted via left-sided minithoracotomy using hybrid surgical approach. Results. Immediate results revealed optimal angiographic and hemodynamic characteristics: normal closure, native pulmonary leaflets covered by the implanted bioprosthesis, no deformity of valve framework and intact pulmonary artery wall. There were no tricuspid obstruction and pressure gradient. Conclusion. Implantation of original transcatheter pulmonary artery valve in a porcine experiment demonstrated its immediate efficacy and safety without the risk of pulmonary artery perforation or displacement.